Glen Allen, Virginia-based Adial Pharmaceuticals (Nasdaq: ADIL) has acquired Azora Therapeutics, a Stanford University spinout developing oral small-molecule therapies for inflammatory diseases, in an all-stock transaction accompanied by a concurrent private placement of up to USD 64 million. The deal marks a decisive pivot for Adial away from its legacy addiction therapeutics franchise toward inflammatory bowel disease, with AT177, a colon-targeted aryl hydrocarbon receptor (AhR) agonist, now the combined company's lead program.
The acquisition was structured as an asset acquisition in which all of Azora's outstanding equity was exchanged for 437,474 shares of Adial common stock and approximately 12,930 shares of Adial Series A non-voting convertible preferred stock, representing 12,930,617 shares on an as-converted basis. No cash consideration was paid to Azora equity holders. Following stockholder approval, former Azora holders will own approximately 51% of Adial on a fully diluted basis, with pre-existing Adial stockholders retaining approximately 7.7% and private placement investors holding approximately 41.3%.
The concurrent financing delivers approximately USD 32 million upfront — including conversion of outstanding notes assumed in the acquisition — through pre-funded warrants priced at USD 2.7489 per warrant. A second tranche of up to USD 32 million becomes available upon Phase I clinical study initiation, expected in mid-2027. The financing was led by Coastlands Capital with participation from Boxer Capital Management, Stonepine Capital Management, and AuGC BioFund, among others. Azora holds worldwide royalty-free rights to its technology, originating from Stanford University's SPARK translational medicine program, and those rights transfer to Adial without geographic restriction.
AT177 is a fully synthetic, patented, oral prodrug of indirubin — the most potent AhR agonist within indigo naturalis, a botanical extract with documented clinical efficacy in ulcerative colitis. Its colon-targeted formulation is designed to concentrate AhR activation at the colonic mucosa while limiting systemic exposure, addressing a key liability of earlier AhR agonist approaches: systemic AhR activation has been associated with immunosuppression and potential long-term safety risks. In preclinical studies, AT177 demonstrated robust local colonic AhR activation with markedly limited systemic drug levels and superior colon-to-systemic selectivity relative to other AhR agonists in development. The asset is currently in IND-enabling studies, with a Phase Ia/Ib proof-of-concept ulcerative colitis clinical trial planned for 2027.